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Background: Non-diabetic chronic kidney disease (CKD) patients are a heterogeneous group with a variety of
prognosis. We investigated the role of subclinical carotid atherosclerosis for the prediction of adverse cardiovascular
(CV) outcomes in these patients, and tried to identify clinical and echocardiographic parameters associated with
subclinical carotid atherosclerosis.
Methods: As a prospective design, 182 asymptomatic non-diabetic CKD patients underwent carotid ultrasonography
and Doppler echocardiography. Carotid atherosclerosis was defined as a carotid intima-media thickness ≥1.0 mm and/or
the presence of plaque.
Results: During the mean follow-up period of 28.8 ± 16.1 months, 23 adverse CV events occurred. Patients with carotid
atherosclerosis (99, 54.4%) showed significantly higher rates of annual CV events than those without (8.6 vs. 1.5%, p <0.001).
Particularly, the presence of carotid plaque was a powerful predictor of adverse CV outcomes (OR 7.80, 95% CI 1.45-45.97).
Clinical parameters associated with the presence of subclinical carotid atherosclerosis were old age, previous history of
hypertension, increased pulse pressure, and higher high-sensitivity C-reactive protein (hs-CRP) level. By echocardiography,
early diastolic mitral annular velocity (E’) and the ratio of early peak transmitral inflow velocity (E) to E’ (E/E’) were
closely related with the presence of carotid atherosclerosis. A multivariate analysis showed that age, hs-CRP, and
E/E’ were significant determinants of carotid atherosclerosis.
Conclusions: Carotid plaque, even subclinical, was closely associated with a poor prognosis in non-diabetic CKD
patients. Increased age, hs-CRP level, and E/E’ ratio may be useful markers suggesting the presence of carotid
atherosclerosis in these patients.
Keywords: Carotid atherosclerosis, Cardiovascular events, Non-diabetic chronic kidney disease, Increased left ventricular
filling pressureBackground
Patients with chronic kidney disease (CKD) are often
regarded as the highest risk population for cardiovascu-
lar (CV) disease. However, CKD patients are a heteroge-
neous group, and there are subgroups at lower risk for
CV complications as well as subgroups with increased
need of intensive medical care and close follow-up. Since* Correspondence: imnksk@gmail.com
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reproduction in any medium, provided the ordiabetes has long been identified as a CV disease risk
equivalent, patients with diabetic CKD usually have in-
creased CV risk and poor prognosis, as compared to
those with non-diabetic CKD. However, the long-term
prognoses of non-diabetic CKD patients are especially
diverse; therefore, non-invasive and effective risk assess-
ments are particularly needed for this group. Athero-
sclerosis is the main pathophysiological link between
CKD and CV disease, and the presence of carotid ath-
erosclerosis, even subclinical, could be a useful maker
predicting adverse CV outcomes [1-4]. To date, current. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in asymptomatic patients at intermediate risk. Therefore,
screening for carotid atherosclerosis may be helpful for
the identification of high-risk group in non-diabetic
CKD patients, although routine screening for carotid
atherosclerosis in all CKD patients (including diabetes)
cannot be justified.
According to the previous multi-ethnic observational
study, subclinical carotid atherosclerosis was closely as-
sociated with significant alterations in myocardial strain
parameters, reflecting incipient myocardial systolic and
diastolic dysfunction [5]. However, no data regarding the
relationship between echocardiographic parameters and
carotid atherosclerosis have been reported in these
patients.
In this study, we examined the impact of subclinical
carotid atherosclerosis, as measured by carotid intima-
media thickness (cIMT) and carotid plaque, on long-
term CV outcomes in asymptomatic non-diabetic CKD
patients, and tried to identify clinical and echocardio-
graphic parameters suggesting the presence of subcli-
nical carotid atherosclerosis in these patients.
Methods
Population
Since January 2008, our hospital began a CV surveillance
program for asymptomatic stable CKD patients. CKD
is defined as low estimated glomerular filtration rate
(eGFR) < 60 mL/min/1.73 m2 with abnormalities of kidney
structure or function, present for > 3 months with implica-
tions for health. To avoid the enrollment of ineligible pa-
tients, those taking any medications that may affect renal
function, such as non-steroidal anti-inflammatory drugs,
antibiotics, and herbal medications at the time of evaluation
were not included. Demographic, laboratory, and clinical
data including classic CV risk factors were obtained.
Additionally, resting ECG, Doppler echocardiography
(Vivid 7; GE Medical, Horton, Norway), and carotid B-mode
ultrasonography (US) (Vivid 7; GE Medical, Horton,
Norway) were performed with patient consent. Two
hundred and thirty-four patients were registered in our
cohort between January 2008 and December 2012.
Fifty-two patients were excluded for the following rea-
sons: incomplete data from echocardiography or ca-
rotid US (n = 11), previously diagnosed atherosclerotic
diseases such as cerebrovascular accidents (n = 7), cor-
onary artery disease (n = 13), peripheral arterial disease
(n = 2), presence of edema at the time of echocardiog-
raphy (n = 12), or previously diagnosed cardiomyopathy
(n = 7). Consequently, data from 182 patients were ana-
lyzed, and informed consent was obtained from each patient.
This study was approved by the Hallym University Sacred
heart hospital Institutional Review Board/Ethics committee
and conducted according to the Declaration of Helsinki.Diagnostic work-up
All echocardiographic images were obtained with stand-
ard techniques using the M-mode, 2D, and Doppler
measurements in accordance with the American Society
of Echocardiography guidelines. LV systolic function was
assessed by LV ejection fraction (LVEF) using the modi-
fied biplane Simpson’s method with apical two- and
four-chamber views. The LV mass was calculated ac-
cording to the recommended ASE formula and indexed
for body surface area (BSA) (LVMI, g/m2). LV diastolic
filling pattern was assessed by the transmitral inflow vel-
ocity curve, including peak E velocity (peak transmitral
velocity during early diastole), deceleration time (DT),
peak A velocity (peak transmitral atrial filling velocity
during late diastole), and E/A ratio. For tissue Doppler
images, 2.0-mm sample volume was sequentially placed
at septal and lateral annular sites and the average of the
two values was used to evaluate the early (E’) and late
(A’) diastolic mitral annular velocities. Filters and gains
were adjusted to minimize background noise and
maximize tissue signal, and the E/E’ ratio was also ob-
tained. The left atrial (LA) volume was also measured
from the apical two- and four-chamber views at end-
systole by tracing the LA borders using planimetry. The
LA volume index (LAVI) was calculated by dividing the
LA volume by BSA.
Ultrasonographical B-mode imaging of bilateral ca-
rotid arteries was also performed with high resolution
real-time US with a 12-MHz linear-assay transducer. Bilat-
eral carotid arteries, carotid bulbs, and internal carotid arter-
ies were examined by two different longitudinal projections,
and 2D images were acquired on the R wave of the electro-
cardiography (ECG), frozen in end-diastole and analyzed
off-line. The cIMT was defined as the distance between the
leading edges of the lumen interface and the media-
adventitia interface at the far wall in plaque-free arterial seg-
ments. Carotid plaque was defined as a focal structure
encroaching into the arterial lumen of at least 0.5 mm or
50% of the surrounding IMT value, or demonstrates a
thickness >1.5 mm as measured from the media-adventitia
interface to the intima-lumen interface [6]. Carotid atheros-
clerosis was defined as carotid intima-media thickness
(cIMT) ≥1.0 mm and/or the presence of plaque.
Follow-up and endpoints
Patients were followed by periodic examination in an
outpatient setting. For patients not followed at our cen-
ter, information was obtained by a telephone interview.
The end of follow-up was determined by the occurrence
of adverse CV events or by the date of last patient con-
tact in the hospital for those without events. CV events
were defined as fatal or non-fatal acute coronary syndrome
(ACS) (e.g., acute myocardial infarction and unstable an-
gina), or cerebrovascular events. ACS was defined using
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levels. In cases of multiple cardiac events, only the first
event was used as the end point of follow-up.
Statistical analysis
Statistical analyses were performed using SPSS version
18.0 (SPSS Inc., Chicago, IL, USA). All variables were
expressed as means ± standard deviations (SDs) or medians
with ranges unless otherwise indicated. The Kolmogorov-
Smirnov test was used to analyze the normality of distribu-
tions, and natural log values were used for skewed data.
Correlations between clinical or echocardiographic fac-
tors and carotid atherosclerosis were evaluated using
Spearman’s rank correlation. By multiple regression ana-
lysis, the effects of clinical and echocardiographic para-
meters on the presence of carotid atherosclerosis were
evaluated and an area under the receiver operating cha-
racteristic (ROC) curve was used to compare various
echocardiographic parameters for predicting carotid
atherosclerosis. Survival curves were derived by the
Kaplan-Meier method; the differences between survival
curves were compared using the log-rank test. The multi-
variate Cox proportional hazard model was used to eva-
luate independent predictors of adverse CV outcomes. A
p-value <0.05 was considered statistically significant.
Results
A total of 182 patients (mean age, 67.8 ± 14.7 years;
males, 96 [52.7%]) were analyzed. Subclinical carotid
atherosclerosis was found in 99 patients (54.4%); the
demographic and biochemical characteristics of the pa-
tients with and without carotid atherosclerosis are com-
pared in Table 1. The mean cIMT value of the patients
with carotid atherosclerosis was 0.95 ± 0.18 mm, and
90.9% of them had carotid plaque. The group with ca-
rotid atherosclerosis was significantly older and had a
higher prevalence of hypertension and increased pulse
pressure. In addition, serum phosphorus level was signifi-
cantly lower and low-density lipoprotein (LDL) choles-
terol, triglyceride, and high-sensitivity C-reactive protein
(hs-CRP) levels were higher in these patients. However,
there were no differences in the amount of proteinuria or
the prevalence of statin use between the two groups.
Carotid atherosclerosis and its relationship with
echocardiographic parameters
Differences in various echocardiographic parameters ac-
cording to the presence of carotid atherosclerosis are
shown in Table 2. The prevalence of LV hypertrophy
was higher in patients with carotid atherosclerosis (43.4
vs. 31.3%, p = 0.043); however, the LV systolic and dia-
stolic volume indices, LVEF, LVMI and LAVI were simi-
lar between the two groups. Interestingly, pronounced
differences were found in markers of elevated LV fillingpressure between the two groups; the E/A ratio (0.72 ±
0.22 vs. 0.83 ± 0.32, p = 0.032) was significantly lower
while the DT (239.2 ± 46.4 vs. 219.3 ± 46.4, p = 0.019)
was longer in patients with carotid atherosclerosis than
in patients without. Furthermore, tissue Doppler echo-
cardiography showed similar findings: E’ (5.6 ± 2.2 vs.
6.6 ± 1.9, p = 0.003) was lower, but the E/E’ ratio (12.5 ±
4.4 vs. 10.2 ± 3.1, p <0.001) was higher in patients with
carotid atherosclerosis (Table 2).
According to the results of correlation analysis, carotid
atherosclerosis had a strong positive association with age
(r = 0.486, p <0.001), history of hypertension (r = 0.228,
p = 0.002), pulse pressure (r = 0.238, p = 0.001), and hs-
CRP level (r = 0.436, p <0.001). For the echocardio-
graphic parameters, carotid atherosclerosis was closely
associated with the E/A ratio (r = − 0.168, p = 0.035), E’
(r = − 0.245, p = 0.001), A’ (r = − 0.209, p = 0.009) and
E/E’ ratio (r = 0.339, p < 0.001). Using these results, a
stepwise multiple regression analysis showed that age
(β = 0.02, p <0.001), hs-CRP level (β = 0.08, p = 0.013)
and E/E’ ratio (β = 0.02, p = 0.034) were significant
determinants of carotid atherosclerosis in non-diabetic
CKD patients, even after adjustments for other well-
known CV risk factors (Table 3). The area under the
ROC curve of age, hs-CRP and E/E’ ratio to predict
carotid atherosclerosis were 0.782 (0.690 - 0.851), 0.745
(0.661 - 0.830), and 0.726 (0.623-0.801), respectively.
When age, hs-CRP and E/E’ were combined, the AUC
significantly increased to 0.884 (Figure 1).
Risk factors for long-term CV outcomes
During the mean follow-up period of 28.8 ± 16.1 months,
23 adverse CV events occurred: 20 cases with and 3
cases without carotid atherosclerosis. Fatal CV events
were occurred in 3 cases at 20.3, 30.3 and 31.5 months
of follow-up. The overall annual CV event rate per
person-year of follow-up was 5.3%, and the rate was sig-
nificantly higher in patients with carotid atherosclerosis
than in those without (8.6 vs. 1.5%, hazard ratio 5.8, log
rank p = 0.004) (Figure 2).
To investigate the effect of subclinical carotid athero-
sclerosis on the occurrence of adverse CV outcomes, we
performed a Cox regression analysis. By univariate ana-
lysis, smoking, history of hypertension, LVH, increased
E/A, E/E’ ratios, carotid plaque, and cIMT values were
all significant predictors. After adjustment for these fac-
tors, only smoking (OR 3.13, 95% CI 1.10-9.09), an in-
creased E/E’ ratio (OR 1.10, 95% CI 1.01-1.21), and the
presence of carotid plaque (OR 7.80, 95% CI 1.45-45.97)
were significant independent predictors of CV events
(Table 4). Considering that cIMT lost its significance in
our multivariate analysis, the presence of carotid plaque
is thought to be the main factor causing adverse CV
events in patients with carotid atherosclerosis.
Table 1 Clinical characteristics of the study population
Clinical characteristics Total (n = 182) Carotid atherosclerosis
+ (n = 99, 54.4%) - (n = 83, 45.6%) p
Age (years) 67.8 ± 14.7 74.5 ± 9.8 59.9 ± 15.6 <0.001
Male, n (%) 96 (52.7) 54 (54.5) 42 (50.6) 0.351
Smoker, n (%) 70 (38.4) 41 (41.4) 29 (34.9) 0.756
Body mass index (kg/m2) 24.1 ± 3.4 23.6 ± 3.1 24.7 ± 3.8 0.065
Hypertension, n (%) 129 (70.8) 81 (81.8) 48 (57.8) 0.001
Systolic blood pressure (mmHg) 134.3 ± 21.0 136.0 ± 23.4 131.5 ± 17.4 0.093
Diastolic blood pressure (mmHg) 75.5 ± 12.0 73.7 ± 12.6 77.6 ± 10.8 0.026
Pulse pressure (mmHg) 58.8 ± 17.1 62.9 ± 18.9 53.9 ± 13.1 <0.001
Baseline laboratory findings
Hemoglobin (g/dL) 11.3 ± 2.1 11.5 ± 2.0 11.3 ± 2.2 0.553
Albumin (g/dL) 3.9 ± 0.6 3.8 ± 0.6 4.0 ± 0.6 0.144
Blood urea nitrogen (mg/dL)* 28.7 (10.8-118.3) 30.9 (10.8-118.3) 27.1 (12.2-99.0) 0.065
Creatinine (mg/dL) 2.6 ± 2.5 2.7 ± 2.0 2.4 ± 1.7 0.229
eGFR (mL/min/1.73 m2) 28.1 ± 16.1 23.6 ± 15.5 30.1 ± 18.5 0.185
Calcium (Ca) 8.8 ± 0.7 8.8 ± 0.6 8.6 ± 0.8 0.128
Phosphorus (P) 3.7 ± 1.2 4.0 ± 1.4 3.5 ± 0.9 0.030
Ca * P product 34.6 ± 9.4 35.4 ± 18.3 34.2 ± 10.8 0.292
Total cholesterol (mg/dL) 163.1 ± 44.8 169.8 ± 41.3 157.6 ± 47.1 0.092
HDL-cholesterol (mg/dL) 47.0 ± 15.2 47.9 ± 16.5 45.9 ± 12.9 0.456
LDL-cholesterol (mg/dL) 99.8 ± 35.2 108.9 ± 35.8 93.2 ± 33.3 0.011
Triglyceride (mg/dL) 112.9 ± 51.7 128.2 ± 51.3 101.6 ± 49.4 0.003
Urine PCR† −1.17 ± 1.42 −1.34 ± 1.27 −0.98 ± 1.57 0.103
hs-CRP (mg/L) † −0.20 ± 1.12 −0.01 ± 1.19 −0.43 ± 0.98 <0.001
Statin use, n (%) 105 (57.6) 61 (61.6) 44 (53.0) 0.041
cIMT (mm) 0.87 ± 0.18 0.95 ± 0.18 0.75 ± 0.09 <0.001
Plaque, n (%) 90 (49.5) 90 (90.9) - -
Abbreviations: HDL, High-density lipoprotein; LDL, Low-density lipoprotein; urine PCR, Urine protein-to-creatinine ratio. *, median with ranges. †, log-transformed.
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In this study, we examined the long-term outcomes
and predictors of subclinical carotid atherosclerosis
among non-diabetic, pre-dialysis CKD patients. With a
prevalence of 54.4%, carotid atherosclerosis was an in-
dependent risk factor for adverse CV outcomes. In
particular, carotid plaque increased the risk of CV
events by 7.8 times. Age, hs-CRP level, and E/E’ ratio
could be significant determinants suggesting the pres-
ence of subclinical carotid atherosclerosis in these
patients.
The number of non-diabetic CKD patients continues
to grow owing to the increasing number of elderly
people and the recent obesity epidemic. Although CKD
itself is considered to be a powerful determinant of CV
mortality, non-diabetic CKD patients are a heteroge-
neous group with a variety of prognoses. The need
for effective risk stratification assumes unprecedentedsignificance in these patients, and identification of ca-
rotid atherosclerosis, even subclinical, could be a useful
tool for prediction of future prognosis.
The prevalence of subclinical carotid atherosclerosis is
<5% in healthy young, and 5-10% among the elderly
people [7]. In certain populations, however, the preva-
lence becomes much higher: 15-25% in subjects with
hypertension or PAD [8,9], and up to 70% in patients
with CAD [10]. Our data showed a fairly high prevalence
of subclinical carotid atherosclerosis in non-diabetic
CKD patients; about half of the patients (54.4%) had ca-
rotid atherosclerosis, and most of them had carotid
plaque. Individuals with carotid atherosclerosis had sig-
nificantly higher rates of adverse CV events compared to
patients without. These findings are in keeping with
those of previous studies, which demonstrated the harm-
ful effect of carotid atherosclerosis on the risk of CV
mortality and morbidity. However, we additionally found
Table 2 Differences in echocardiographic parameters according to the presence of carotid atherosclerosis
Clinical characteristics Total (n = 182) Carotid atherosclerosis
+ (n = 99, 54.4%) - (n = 83, 45.6%) p
LV end-diastolic diameter (mm) 47.3 ± 5.7 46.9 ± 6.7 47.7 ± 4.2 0.392
LV end-systolic diameter (mm) 31.7 ± 5.6 31.5 ± 6.1 32.1 ± 5.2 0.555
LV end-diastolic volume index (mL/m2) 52.1 ± 9.1 48.9 ± 12.8 55.6 ± 13.3 0.109
LV end- systolic volume index (mL/m2) 21.3 ± 9.2 20.6 ± 9.2 22.2 ± 9.1 0.373
LVMI (g/m2) 99.3 ± 29.5 94.3 ± 27.3 101.0 ± 31.2 0.170
LVEF (%) 59.1 ± 9.7 58. 0 ± 11.0 60.4 ± 7.7 0.161
LAVI (mL/m2) 42.2 ± 17.3 42.9 ± 17.7 39.5 ± 16.9 0.191
LVH, n (%) 69 (37.9) 43 (43.4) 26 (31.3) 0.043
Mitral inflow velocities (mean ± SD)
E (cm/s) 64.7 ± 19.0 64.1 ± 19.2 70.3 ± 18.9 0.101
A (cm/s) 84.3 ± 20.4 85.5 ± 18.6 82.9 ± 22.2 0.439
E/A ratio 0.77 ± 0.28 0.72 ± 0.22 0.83 ± 0.32 0.032
DT (ms) 231.0 ± 48.0 239.2 ± 46.4 219.3 ± 46.4 0.019
Tissue Doppler parameters
E’ (cm/s) 6.1 ± 2.1 5.6 ± 2.2 6.6 ± 1.9 0.003
A’ (cm/s) 8.9 ± 1.9 8.7 ± 2.2 9.2 ± 1.6 0.090
E/E’ ratio 11.5 ± 4.1 12.5 ± 4.4 10.2 ± 3.1 <0.001
Abbreviations: LVMI, LV mass index; LVEF, LV ejection fraction; LAVI, Left atrial volume index; E, Early peak transmitral inflow velocity; A, late diastolic transmitral
inflow velocity; DT, Deceleration time; E’, Early diastolic mitral annular velocity; A’, Late diastolic mitral annular velocity.
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of CV outcomes. The presence of carotid plaque was as-
sociated with a 7.8 times higher risk of CV events,
whereas cIMT lost its significance in our multivariate




Age 0.02 (0.01, 0.02)
Hypertension 0.29 (0.11, 0.48)
Systolic BP (mmHg) 0.01 (−0.01, 0.01)
Diastolic BP (mmHg) −0.01 (−0.02, -0.01)
Pulse pressure (mmHg) 0.01 (0.01, 0.02)
BMI (kg/m2) −0.01 (−0.04, 0.01)
Urine PCR (g/g)* −0.04 (−0.10, -0.01)
hs-CRP* 0.09 (0.02, 0.15)
Statins 0.11 (−1.10, 1.26)
Echocardiographic data
LVH 0.13 (−0.02, 0.28)
LVEF −0.01 (−0.01, 0.01)
E/A ratio −0.28 (−0.56, 0.01)
E’ −0.05 (−0.08, -0.02)
E/E’ ratio 0.04 (0.02, 0.06)
*, log-transformed.the main causes of non-diabetic CKD in our population
were hypertension, which is a main determinant of in-
creasing cIMT. In fact, the value of cIMT as a marker of
generalized atherosclerosis has recently been called into
question since the primary predictors of increased cIMTwith carotid atherosclerosis in non-diabetic CKD
Multivariate analysis
P Unstandardized coefficient P
<0.001 0.02 (0.01, 0.02) <0.001
0.002 0.12 (−0.06, 0.30) 0.199
0.103 - -
0.026 −0.01 (−0.06, 0.31) 0.177
<0.001 0.01 (−0.01, 0.01) 0.267
0.176
0.097 - -






<0.001 0.02 (0.01, 0.04) 0.034
Figure 1 ROC curves for age, hs-CRP, and the E/E’ ratio for the prediction of carotid atherosclerosis. When age, hs-CRP and the E/E’ ratio
were combined, the AUC significantly increased to 0.884.
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flect the atherosclerotic process [11,12]. Moreover, the
2007 European guidelines on hypertension have empha-
sized that treatment-induced regression of asymptomatic
organ damage could reduce the risk of fatal and nonfatal
CV events. This has been shown with the treatment-
induced regression of electrocardiographic LVH [13], the
echocardiographic LVH [14], LVM and left atrial size
[15]. However according to a recent analysis of the
ELSA study, the treatment-induced cIMT changes in the
carotid arteries failed to document a predictive value for
CV events [16]. Therefore, the use and enthusiasm for
cIMT as a marker of subclinical organ damage has con-
siderably declined over the last years. Carotid plaque, in
contrast, is regarded as a more representative marker of
atherosclerotic burden, and it may have greater predict-
ive power for CV outcomes [17].
In our study, carotid plaque, a representative marker
of atherosclerosis, was a main predictor of adverse CV
events in non-diabetic CKD patients who were not yeton dialysis treatment. This finding would support the re-
sults of SHARP (Study of Heart And Renal Protection)
study which evaluated the anti-atherogenic effect of sta-
tin in large cohort of patients with pre-dialysis CKD and
patients undergoing dialysis. The study showed a signifi-
cant reduction in major CV events [18] with statin treat-
ment, suggesting that atherosclerosis does play an
important role for adverse CV events. However, accord-
ing to the results of another two large clinical trials
conducted only in patients receiving hemodialysis, 4D
(Deutsche Diabetes Dialyse Studie) [19] and AURORA
(A study to evaluate the Use of Rosuvastatin in sub-
jects On Regular hemodialysis: an Assessment of sur-
vival and cardiovascular e) [20], statins showed little or
no benefit as primary CV diseases prevention. With
these, the pathophysiology of CV disease in non-dialysis
CKD patients seems to be more strongly associated with
atherosclerosis compared to that of patients receiving dia-
lysis treatment. This may be why the carotid plaque pre-
dicted adverse CV events in our study.
Figure 2 Cardiovascular event-free survival in analyses by cIMT, carotid plaque and carotid atherosclerosis. The presence of carotid
atherosclerosis was significantly associated with poor prognosis in non-diabetic CKD patients.
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Table 4 Risk factors for adverse CV outcomes among non-diabetic CKD patients
Parameters Adverse CV events Univariate analysis Multivariate analysis
+ (n = 23) - (n = 159) P HR (95% CI) P
Age (years)† 72.5 ± 11.2 67.2 ± 15.1 0.098 1.05 (0.91-1.01) 0.087
Male, n (%) 13 (56.5) 83 (52.2) 0.740 - -
Smokers, n (%)† 13 (56.5) 57 (35.8) 0.012 3.13 (1.10-9.09) 0.036
Hypertension, n (%)† 20 (87.0) 109 (68.5) 0.043 1.61 (0.88-2.51) 0.101
SBP (mmHg) 138.9 ± 31.0 133.6 ± 19.2 0.181 - -
DBP (mmHg) 78.0 ± 14.0 75.1 ± 11.7 0.150 - -
Pulse pressure (mmHg) 60.9 ± 24.6 58.5 ± 15.8 0.552 - -
BMI (kg/m2) 24.1 ± 3.2 24.3 ± 3.7 0.746
Serum creatinine (mg/dL) 2.8 ± 3.1 2.7 ± 2.4 0.910 - -
LDL-cholesterol (mg/dL) 100.5 ± 34.1 96.2 ± 41.0 0.684 - -
Urine PCR* −0.97 ± 1.22 −1.2 ± 1.45 0.426 - -
hs-CRP (mg/L) *† 0.03 ± 1.27 −0.23 ± 1.10 0.220 1.22 (0.58-1.28) 0.486
Echocardiography
LVH† 13 (56.5) 56(35.2) 0.029 2.01 (0.81-5.34) 0.128
LVEF 58.3 ± 9.8 59.1 ± 9.7 0.778 - -
LVMI 112.0 ± 27.9 101.4 ±29.5 0.133 - -
E/A ratio† 0.64 ± 0.12 0.78 ± 0.30 0.013 0.02 (0.001-0.55) 0.022
E/E’ ratio† 13.7 ± 5.21 11.3 ± 3.7 0.003 1.10 (1.01-1.21) 0.042
Carotid plaque, n (%)† 18 (78.3) 72(45.3) 0.001 7.80 (1.45-45.97) 0.017
Carotid IMT (mm) † 0.95 ± 0.13 0.84 ± 0.15 0.010 10.58 (0.43-26.87) 0.149
†, p <0.05 between patients with and without adverse CV events. *, log-transformed.
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rameters suggesting the presence of subclinical carotid
atherosclerosis in our patient group. According to our
results, increasing age, a high hs-CRP level, and a high
E/E’ ratio were closely associated with the presence of
subclinical carotid atherosclerosis. Interestingly, we
found that markers of increased LV filling pressure
such as the E/A ratio, DT, E’ and E/E’ ratio were
closely associated with carotid plaque as well as cIMT. In
particular, the effect of an elevated E/E’ ratio on the pres-
ence of carotid atherosclerosis was independent of other
CV risk factors, including old age, hypertension, high
pulse pressure, hs-CRP level, and the use of statins. In-
deed, the E/E’ ratio is a representative marker of increased
LV filling pressure and is usually associated with LV dia-
stolic dysfunction, ultimately leading to LV systolic dys-
function and overt heart failure [21,22]. In fact, several
longitudinal studies have revealed that the LAVI [23] and
E/E’ ratio [24,25] can serve as independent predictors of
CV and all-cause mortality in dialysis patients. Similarly,
in our study, the E/E’ ratio was an independent risk factor
for both carotid atherosclerosis and poor CV outcomes.
The close association between the E/E’ ratio and carotid
atherosclerosis explain why an elevated E/E’ ratio is astrong and independent predictor of adverse CV out-
comes in various populations.
Several pathophysiologic mechanisms can be proposed
for the link between a high LV filling pressure and ca-
rotid atherosclerosis. First, high blood pressure might be
one of them. The findings noted on transmitral flow and
tissue Doppler findings may be reflective of more signifi-
cant hypertensive heart disease; thus, the link may be
hypertension causing abnormalities in the echocardio-
graphic parameters and contributing to the development
of carotid disease. Another possible explanation is vascu-
lar stiffness. As our data show, those patients with ca-
rotid atherosclerosis had a significantly higher pulse
pressure than did their counterparts. In patients with
end-stage renal disease, increased vascular stiffness and
a resultant higher brachial-ankle pulse wave velocity was
closely associated with advanced carotid atherosclerosis
[26]. Increased vascular stiffness is an important aggra-
vating factor in LV systolic and diastolic dysfunction
leading to a rise in LV filling pressure [27]. Third,
chronic low-grade inflammation may be related to the
increase in LV filling pressure and carotid atherosclerosis.
Inflammatory cytokines such as interleukin-6 (IL-6),
tumor necrosis factor-α, and hs-CRP are well-established
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tory cytokines could induce LV diastolic dysfunction or
even diastolic heart failure via effects on both myocyte
contractility and the extracellular matrix [30].
The current study has several limitations. First, the
causal relationship between carotid atherosclerosis and
increased LV filling pressure could not be precisely iden-
tified. Because both LV filling pressure and cIMT are
known to arise in early-stage kidney disease, accelerated
atherosclerosis could affect on the increase in LV filling
pressure. A long-term follow-up study is needed to ad-
dress this issue. Second, as this study was conducted at a
single hospital, our results are not validated or replicated
for any other data set. In addition, although we included
only stable CKD patients, the possibility of acute renal
deterioration during study period or the frequency of
renal function measures may be one of the limitations of
our study. Third, although patients with a clinically ap-
parent volume overload status were excluded, long-
standing subclinical volume overload may be present
in CKD patients, and volume-overloaded hearts could
have been misclassified as having increased LV filling
pressure. At last, a relatively small size of population is
a limitation of our study.
Conclusions
Subclinical carotid atherosclerosis is common in non-
diabetic CKD patients and closely associated with adverse
CV events. In particular, carotid plaque was an independ-
ent prognostic factor for long-term CV outcomes. Along
with such well-known risk factors as old age and higher
hs-CRP level, increased E/E’ ratio was an important pre-
dictor suggesting the presence of carotid atherosclerosis in
non-diabetic CKD patients.
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